What does an elevated gamma‑glutamyl transferase indicate in a patient receiving interferon therapy?

Elevated GGT During Interferon Therapy

An elevated GGT in a patient receiving interferon therapy most commonly indicates drug-induced hepatotoxicity from the interferon itself, though it may also reflect underlying cholestatic liver injury or progression of the underlying liver disease being treated. 1

Primary Interpretation: Drug-Induced Hepatotoxicity

The FDA labeling for interferon explicitly warns that elevations of AST and/or ALT (up to 25-fold) have been observed during interferon therapy, with hepatic toxicity being a recognized adverse effect 1. While the label specifically mentions transaminases, GGT elevation falls within the spectrum of drug-induced liver injury from interferon.

Key clinical actions when GGT is elevated:

• If severe hepatic enzyme elevations develop, interferon dosage should be reduced by 50% or therapy interrupted until the adverse reaction abates 1
• Frequent assessment of liver function is recommended, particularly in patients with advanced hepatic disease where interferon may accumulate 1
• Patients under age 1 year require monthly liver function monitoring due to higher incidence of hepatotoxicity 1

Secondary Considerations: Cholestatic Pattern

GGT elevation may indicate a cholestatic pattern of liver injury 2. According to ACR guidelines, concomitantly elevated GGT confirms that an elevated alkaline phosphatase originates from the liver and indicates cholestasis 2. This could represent:

• Drug-induced cholestasis from interferon
• Intrahepatic cholestasis related to the underlying condition
• Progression of underlying liver disease despite treatment

Prognostic Implications in Hepatitis C Context

If the patient is receiving interferon for hepatitis C (the most common indication historically), elevated GGT carries additional significance:

• Baseline elevated GGT is strongly associated with diminished treatment response - including reduced week 20 response, end-of-treatment response, and sustained virological response 3
• Elevated GGT predicts both poor virological response AND worse long-term clinical outcomes in patients with advanced liver disease 3
• Normal GGT levels (<2× ULN) are independently predictive of sustained virological response, while GGT >2× ULN predicts treatment failure 4, 5
• Elevated GGT is associated with more severe hepatic fibrosis or cirrhosis, which may account for poor interferon response 6

Clinical Algorithm

When you encounter elevated GGT during interferon therapy:

1. Determine the magnitude of elevation:

   • GGT >2× ULN suggests significant hepatotoxicity or cholestasis 4, 7
   • GGT >3.2× ULN indicates high risk for adverse outcomes 8

2. Check concurrent liver enzymes:

   • If AST/ALT are also markedly elevated (>5× ULN), this represents significant hepatotoxicity requiring dose modification 1
   • If alkaline phosphatase is also elevated, this confirms cholestatic injury pattern 2

3. Assess for drug-induced liver injury:

   • Even if conventional DILI thresholds aren't met, marked GGT elevation alone may warrant drug discontinuation 7
   • Consider RUCAM scoring if DILI is suspected

4. Modify therapy:

   • Reduce interferon dose by 50% or interrupt therapy if severe 1
   • Monitor liver function frequently during dose adjustment 1

5. Evaluate for alternative causes:

   • Rule out biliary obstruction if cholestatic pattern present (ultrasound as first-line) 2
   • Consider underlying disease progression
   • Exclude other hepatotoxic medications

Important Caveats

• GGT is highly sensitive but poorly specific for liver injury 9. It can be elevated in numerous non-hepatic conditions including metabolic syndrome, cardiovascular disease, and chronic kidney disease
• Persistent GGT elevation after drug withdrawal, particularly if peak GGT was >2× ULN, is associated with failure to achieve full remission 7
• In patients with pre-existing advanced liver disease, interferon may accumulate and cause progressive hepatotoxicity 1

The bottom line: Elevated GGT during interferon therapy should prompt immediate evaluation for drug-induced hepatotoxicity, dose reduction or discontinuation if severe, and consideration of the patient's likelihood of treatment response given that elevated GGT predicts both poor virological outcomes and worse long-term prognosis.